Results 181 to 190 of about 1,861,365 (381)

Lysine-specific demethylase 1 (LSD1) suppresses cellular senescence by riboflavin uptake-dependent demethylation activity

Scientific Reports
Cellular senescence is defined as a permanent proliferation arrest caused by various stresses, including DNA damage. We have recently identified the riboflavin transporter SLC52A1, whose expression is increased in response to senescence-inducing stimuli.
Taiichi Osumi, Taiki Nagano, Tetsushi Iwasaki, Jotaro Nakanishi, Kazuyuki Miyazawa, Shinji Kamada   +5 more
doaj   +1 more source

Cellular Senescence After Single and Repeated Balloon Catheter Denudations of Rabbit Carotid Arteries [PDF]

, 2001
M. J. Fenton, Steve Barker, David J. Kurz, Jorge D. Erusalimsky   +3 more
openalex   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

Involvement of REL/NF-B Transcription Factors in Cellular Senescence [PDF]

, 2001
David Bernard, Didier Monté, Bernard Vandenbunder, Corinne Abbadie   +3 more
openalex   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

The miR-30-5p/TIA-1 axis directs cellular senescence by regulating mitochondrial dynamics

Cell Death and Disease
Senescent cells exhibit a diverse spectrum of changes in their morphology, proliferative capacity, senescence-associated secretory phenotype (SASP) production, and mitochondrial homeostasis.
Hyosun Tak, Seongho Cha, Youlim Hong, Myeongwoo Jung, Seungyeon Ryu, Sukyoung Han, Seung Min Jeong, Wook Kim, Eun Kyung Lee   +8 more
doaj   +1 more source

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias, Ana Oitabén, Sonia Zumalave, Bernardo Rodriguez‐Martin, María Gallardo‐Gómez, Martín Santamarina, Ana Pequeño‐Valtierra, Laura Juaneda‐Magdalena, Ramón García‐Escudero, José Luis López‐Cedrún, Máximo Fraga, José M. C. Tubio, Mónica Martínez‐Fernández   +12 more
wiley   +1 more source

Cellular Senescence: Defining a Path Forward

Cell, 2019
V. Gorgoulis, P. Adams, A. Alimonti, D. Bennett, O. Bischof, C. Bishop, J. Campisi, M. Collado, K. Evangelou, G. Ferbeyre, Jesús Gil, E. Hara, V. Krizhanovsky, D. Jurk, A. Maier, M. Narita, L. Niedernhofer, J. Passos, P. Robbins, C. Schmitt, J. Sedivy, K. Vougas, T. Zglinicki, Daohong Zhou, M. Serrano, M. Demaria   +25 more
semanticscholar   +1 more source

Characterization of cellular senescence in aging skeletal muscle

Nature Aging, 2022
Xu Zhang, Leena Habiballa, Zaira Aversa, Yan Er Ng, A. Sakamoto, Davis A. Englund, Vesselina M. Pearsall, T. White, M. Robinson, D. Rivas, Surendra Dasari, Adam J. Hruby, A. Lagnado, Sarah K. Jachim, A. Granic, A. Sayer, D. Jurk, Ian R. Lanza, S. Khosla, R. Fielding, K. Nair, M. Schafer, J. Passos, N. LeBrasseur   +23 more
semanticscholar   +1 more source